The safety of cabotegravir in pregnancy: a systematic review and meta-analysis.

ABSTRACT:

Background

HIV remains an important global public health crisis. Antiretroviral treatment has been essential to suppress viral replication, and in at-risk individuals, antiretroviral pre-exposure prophylaxis drugs (PrEP) lower transmission rates. Unfortunately, current oral regimens require stringent daily adherence to be effective. Long-acting intra-muscular cabotegravir potentially averts the issue of poor patient adherence. This formulation has the potential to cause a breakthrough in mitigating the spread of HIV; however, safety in pregnancy is still to be established. This systematic review aimed to assess the data relating to the safety and prevalence of adverse effects of cabotegravir in pregnancy.

Methods and analysis

The research followed the PRISMA guidelines and C

SUBMITTER: Jasper A 

PROVIDER: S-EPMC12613714 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature